<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313477226</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313477226</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical characteristics and risk factors of intracranial hemorrhage in systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gao</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477226">1</xref>
<xref ref-type="fn" rid="fn1-0961203313477226">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>ZL</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477226">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>MT</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477226">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Han</surname><given-names>SM</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477226">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dang</surname><given-names>YQ</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313477226">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>FC</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477226">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shi</surname><given-names>TY</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477226">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>LN</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477226">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zeng</surname><given-names>XF</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477226">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313477226"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203313477226"><label>1</label>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China</aff>
<aff id="aff2-0961203313477226"><label>2</label>Department of Epidemiology and Statistics, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China</aff>
<aff id="aff3-0961203313477226"><label>3</label>Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China</aff>
<author-notes>
<fn fn-type="equal" id="fn1-0961203313477226"><label>*</label><p>N Gao and ZL Wang contributed equally to this study.</p></fn>
<corresp id="corresp1-0961203313477226">Xiao-Feng Zeng, Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China. Email: <email>zengxfpumc@yahoo.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>453</fpage>
<lpage>460</lpage>
<history>
<date date-type="received"><day>19</day><month>8</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We enrolled and reviewed 26 medical records of systemic lupus erythematosus (SLE) with intracranial hemorrhage (cases) and 104 randomly matched records of SLE without intracranial hemorrhage (controls) out of 6653 admitted patients at Peking Union Medical College Hospital from 1994 to 2012, to analyze the clinical characteristics and risk factors of intracranial hemorrhage in SLE. The incidence of SLE with intracranial hemorrhage was only 0.39% within the last 18 years at Peking Union Medical College Hospital. However, the in-hospital fatality rate was quite high (23.1%). Headache was the most common symptom (53.5%) in SLE patients with intracranial hemorrhage. The anatomical localization of the hemorrhages in the brain was predominantly located in the cerebrum. Intracranial hemorrhage could happen in either stable or active SLE patients. SLE patients with intracranial hemorrhage presented other neuropsychiatric syndromes defined by the American College of Rheumatology (ACR) in 1999, thrombocytopenia and antiphospholipid syndrome more frequently than controls. Thrombocytopenia was the independent risk factor for intracranial hemorrhage coexisting with SLE (OR = 3.687, 95% CI 1.510–9.001, <italic>p</italic> = 0.004).</p>
</abstract>
<kwd-group>
<kwd>intracranial hemorrhage</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>thrombocytopenia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313477226" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases. The prevalence of lupus is geographically different (0.03–0.2%).<sup><xref ref-type="bibr" rid="bibr1-0961203313477226">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203313477226">2</xref></sup> Multiple organs are involved in SLE, including skin, mucosa, joints, pleura, lung, kidney, and the nervous system. Although the life expectancy of lupus patients has improved during recent decades, SLE is still a life-threatening disease. The main causes of death in SLE patients remain infection and organ damage,<sup><xref ref-type="bibr" rid="bibr3-0961203313477226">3</xref><xref ref-type="bibr" rid="bibr4-0961203313477226"/>–<xref ref-type="bibr" rid="bibr5-0961203313477226">5</xref></sup> although cardiovascular and cerebrovascular events can also cause death in some patients.<sup><xref ref-type="bibr" rid="bibr6-0961203313477226">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203313477226">7</xref></sup></p>
<p>As one category of the neuropsychiatric syndromes of SLE (NPSLE), cerebrovascular disease is of importance.<sup><xref ref-type="bibr" rid="bibr8-0961203313477226">8</xref></sup> Our clinical experience has shown that an intracranial hemorrhage in SLE patients is often lethal and disabling. However, intracranial hemorrhage in SLE patients is rarely reported, and most of the reports are of subarachnoid hemorrhage.<sup><xref ref-type="bibr" rid="bibr9-0961203313477226">9</xref><xref ref-type="bibr" rid="bibr10-0961203313477226"/><xref ref-type="bibr" rid="bibr11-0961203313477226"/><xref ref-type="bibr" rid="bibr12-0961203313477226"/><xref ref-type="bibr" rid="bibr13-0961203313477226"/><xref ref-type="bibr" rid="bibr14-0961203313477226"/>–<xref ref-type="bibr" rid="bibr15-0961203313477226">15</xref></sup> Therefore, in this study, we retrospectively analyzed medical data of 26 SLE patients with intracranial hemorrhages and 104 SLE patients without intracranial hemorrhage to explore the characteristics and risk factors for intracranial hemorrhage in SLE patients.</p>
</sec>
<sec id="sec2-0961203313477226" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0961203313477226" sec-type="subjects"><title>Patients</title>
<p>All patients were admitted to Peking Union Medical College Hospital (PUMCH) between January 1994 and January 2012. For SLE patients with intracranial hemorrhage (cases), the inclusion criteria were as follows: (1) patients fulfilled the revised American College of Rheumatology (ACR) classification criteria for SLE (1997);<sup><xref ref-type="bibr" rid="bibr16-0961203313477226">16</xref></sup> and (2) patients had an intracranial hemorrhage diagnosed according to nervous system manifestations, lumbar puncture, and imaging examinations. Patients with traumatic intracranial hemorrhage or major data that were incomplete were excluded from the study. Based on a careful review, we identified 26 cases of SLE with intracranial hemorrhage out of 6653 SLE cases (0.39%) meeting our research standards. For SLE patients without intracranial hemorrhage (controls), the inclusion criteria were as follows: (1) patients fulfilled the 1997 ACR classification criteria for SLE; and (2) intracranial hemorrhage was excluded according to nervous system manifestations, lumbar puncture, or imaging examinations. For each case (<italic>n</italic> = 26), four controls (<italic>n</italic> = 104) were randomly selected among the contemporaneous SLE patients without intracranial hemorrhage and category matched by sex and age.</p>
</sec>
<sec id="sec4-0961203313477226"><title>Clinical and laboratory data collected</title>
<p>We analyzed and compared the following data: gender, age at SLE onset, age at admission to PUMCH, disease duration, serositis, nephropathy, hematological disturbance, nervous system disturbance (including all the neuropsychiatric syndromes defined by the 1999 ACR criteria for NPSLE), microscopic hematuria, albuminuria, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hypocomplimentemia, thrombocytopenia (classified as severe (platelet count: &lt; 20 × 10<sup>9</sup>/l), moderate (platelet count: 20–50 × 10<sup>9</sup>/l), and mild (platelet count &gt; 50 × 10<sup>9</sup>/l and &lt;100 × 10<sup>9</sup>/l)), prolonged prothrombin time (PT, defined as 3 seconds (s) longer than the reference), lupus anticoagulant (LA), anti-nuclear antibody, anti-double-stranded DNA (anti-dsDNA) antibody, anti-ENA antibodies (including anti-SSA, anti-SSB, anti-Sm, anti-RNP, and anti-rRNP antibody), anti-cardiolipin (IgG-aCL) antibody, SLE disease activity index (SLEDAI, stratified to stable (&lt;5), mild active (5–9), moderate active (10–14), and severe active (&gt;14)),<sup><xref ref-type="bibr" rid="bibr17-0961203313477226">17</xref></sup> antiphospholipid syndrome diagnosed according to revised classification criteria for antiphospholipid syndrome,<sup><xref ref-type="bibr" rid="bibr18-0961203313477226">18</xref></sup> hypertension (defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), diabetes (defined as fasting glucose level ≥126 mg per deciliter, two-hour glucose level ≥200 mg per deciliter, or both), personal history of smoking (defined as having smoked at least 100 cigarettes),<sup><xref ref-type="bibr" rid="bibr19-0961203313477226">19</xref></sup> and family history of cerebrovascular disease. Two or more occasions of IgG-aCL and LA, at least 12 weeks apart, were recorded. The laboratory parameters and SLEDAI were collected at the time of admission to the hospital in both the case and control groups.</p>
</sec>
<sec id="sec5-0961203313477226"><title>Antibodies assay</title>
<p>Anti-nuclear antibody (ANA) was measured by indirect immunofluorescence (IIF) using HEp-2 cell substrates. Anti-dsDNA antibody was tested by IIF using flagellate protoctista substrates and enzyme-linked immunosorbent assay (ELISA). Anti-ENA antibodies were determined by immunodiffusion assay. IgG-aCL antibody was detected by ELISA. LA was measured using activated partial thromboplastin time (APTT)-based assay.</p>
</sec>
<sec id="sec6-0961203313477226"><title>Statistical analysis</title>
<p>To analyze the differences between two groups, Student’s <italic>t</italic> test or Wilcoxon rank test were used for numerical data according to the normality, and the Chi square test was used for the qualitative data. Variables with a significant <italic>p</italic> value between two groups in the single factor analysis were computed to the multivariate logistic regression model to predict the independent risk factors for SLE with intracranial hemorrhage. The <italic>p</italic> value was two tailed and interpreted as significant when the value was &lt;0.05. SPSS software, version 17 (Chicago, IL, USA) was used for all of the statistical descriptions and inferences.</p>
</sec>
</sec>
<sec id="sec7-0961203313477226" sec-type="results"><title>Results</title>
<sec id="sec8-0961203313477226"><title>General clinical profiles of the case group</title>
<p>Of the SLE patients with intracranial hemorrhage, 23/26 (88.5%) were female. The mean ( ± SE) age when cases experienced intracranial hemorrhage was 36.0 ± 2.8 years. The mean ( ± SE) age of SLE patients at the time of SLE flare-up and the mean ( ± SE) duration of SLE before intracranial hemorrhage were 30.8 ± 2.4 years (range 13–53 years) and 60.3 ± 11.9 months (range 0.4–240 months), respectively. The short-term prognosis of intracranial hemorrhage in SLE patients was very poor, with a rate of in-hospital fatality of 23.1% (<xref ref-type="table" rid="table1-0961203313477226">Table 1</xref>).
<table-wrap id="table1-0961203313477226" position="float"><label>Table 1</label><caption><p>A comparison of demographics, clinical manifestations, and traditional intracranial hemorrhage risk factors between cases and controls</p></caption>
<graphic alternate-form-of="table1-0961203313477226" xlink:href="10.1177_0961203313477226-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Variable</th>
<th>Cases</th>
<th>Controls</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td><italic>Demographics</italic></td>
</tr>
<tr>
<td>Female sex <italic>n</italic>, (%)</td>
<td>23/26 (88.5)</td>
<td>96/104 (92.3)</td>
<td>0.813</td>
</tr>
<tr>
<td>Age, years, mean ± SE</td>
<td>36.0 ± 2.8</td>
<td>34.0 ± 1.3</td>
<td>0.511</td>
</tr>
<tr>
<td><italic>Clinical manifestations</italic></td>
</tr>
<tr>
<td>Flare-up age, years, mean ± SE</td>
<td>30.8 ± 2.4</td>
<td>28.6 ± 1.2</td>
<td>0.418</td>
</tr>
<tr>
<td>Disease duration, months, mean ± SE</td>
<td>60.3 ± 11.9</td>
<td>68.6 ± 8.8</td>
<td>0.742</td>
</tr>
<tr>
<td>Fatality, <italic>n</italic> (%)</td>
<td>6/26 (23.1)</td>
<td>6/104 (5.8)</td>
<td>0.019</td>
</tr>
<tr>
<td>Serositis, <italic>n</italic> (%)</td>
<td>13/26 (50)</td>
<td>42/104 (40.4)</td>
<td>0.375</td>
</tr>
<tr>
<td>Nephropathy, <italic>n</italic> (%)</td>
<td>17/26 (65.4)</td>
<td>81/104 (77.9)</td>
<td>0.186</td>
</tr>
<tr>
<td> Microscopic hematuria, <italic>n</italic> (%)</td>
<td>13/23 (56.5)</td>
<td>53/99 (53.5)</td>
<td>0.796</td>
</tr>
<tr>
<td> Albuminuria, <italic>n</italic> (%)</td>
<td>14/21 (60.9)</td>
<td>55/100(55)</td>
<td>0.609</td>
</tr>
<tr>
<td>Hematological disturbance, <italic>n</italic> (%)</td>
<td>14/26 (53.8)</td>
<td>35/104 (33.7)</td>
<td>0.057</td>
</tr>
<tr>
<td> Thrombocytopenia, <italic>n</italic> (%)</td>
<td>14/26 (53.8)</td>
<td>25/104 (24)</td>
<td>0.003</td>
</tr>
<tr>
<td> Autoimmune hemolytic anemia, <italic>n</italic> (%)</td>
<td>0 (0)</td>
<td>5 /104 (4.8)</td>
<td>0.569</td>
</tr>
<tr>
<td> Leukocytopenia, <italic>n</italic> (%)</td>
<td>0 (0)</td>
<td>5/104 (4.8)</td>
<td>0.569</td>
</tr>
<tr>
<td>Nervous system disturbance (excluding intracranial hemorrhage)</td>
<td>12/26 (46.2)</td>
<td>24/104 (23.1)</td>
<td>0.019</td>
</tr>
<tr>
<td> Cerebral infarction, <italic>n</italic> (%)</td>
<td>6/26 (23)</td>
<td>1/104 (1.0)</td>
<td>–</td>
</tr>
<tr>
<td> Headache, <italic>n</italic> (%)</td>
<td>5/26 (19.2)</td>
<td>4/104 (3.8)</td>
<td>–</td>
</tr>
<tr>
<td> Psychosis, <italic>n</italic> (%)</td>
<td>2/26 (7.7)</td>
<td>3/104 (2.9)</td>
<td>–</td>
</tr>
<tr>
<td> Anxiety disorder, <italic>n</italic> (%)</td>
<td>1/26 (3.8)</td>
<td>1/104 (1.0)</td>
<td>–</td>
</tr>
<tr>
<td> Peripheral nervous system disorders, <italic>n</italic> (%)</td>
<td>–</td>
<td>5/104(4.8)</td>
<td>–</td>
</tr>
<tr>
<td> Seizures disorder, <italic>n</italic> (%)</td>
<td>–</td>
<td>4/104 (3.8)</td>
<td>–</td>
</tr>
<tr>
<td> Mood disorder, <italic>n</italic> (%)</td>
<td>–</td>
<td>2/104 (1.9)</td>
<td>–</td>
</tr>
<tr>
<td> Cognition disorder, <italic>n</italic> (%)</td>
<td>–</td>
<td>1/104 (1.0)</td>
<td>–</td>
</tr>
<tr>
<td>Antiphospholipid syndrome</td>
<td>5/26(30.8)</td>
<td>4/104(7.7)</td>
<td>0.02</td>
</tr>
<tr>
<td>Elevated ESR, <italic>n</italic> (%)</td>
<td>18/22 (78.3)</td>
<td>77/102 (75.5)</td>
<td>0.779</td>
</tr>
<tr>
<td>Elevated CRP, <italic>n</italic> (%)</td>
<td>11/22 (50)</td>
<td>33/99 (33.3)</td>
<td>0.142</td>
</tr>
<tr>
<td>Hypocomplementemia, <italic>n</italic> (%)</td>
<td>16/23 (66.7)</td>
<td>71/103 (68.9)</td>
<td>0.830</td>
</tr>
<tr>
<td>Prolonged PT, <italic>n</italic> (%)</td>
<td>3/21 (14.3)</td>
<td>4/97 (4.1)</td>
<td>0.201</td>
</tr>
<tr>
<td>LA, <italic>n</italic> (%)</td>
<td>5/18(27.8)</td>
<td>12/62(19.4)</td>
<td>0.659</td>
</tr>
<tr>
<td>ANA, <italic>n</italic> (%)</td>
<td>26/26 (100)</td>
<td>104/104 (100)</td>
<td>1.0</td>
</tr>
<tr>
<td>Anti-dsDNA antibody, <italic>n</italic> (%)</td>
<td>9/26 (34.6)</td>
<td>53/104 (51)</td>
<td>0.136</td>
</tr>
<tr>
<td>Anti-Sm antibody, <italic>n</italic> (%)</td>
<td>11/25 (44)</td>
<td>35/103 (34)</td>
<td>0.349</td>
</tr>
<tr>
<td>Anti-RNP antibody, <italic>n</italic> (%)</td>
<td>13/25 (52)</td>
<td>48/103 (46.6)</td>
<td>0.628</td>
</tr>
<tr>
<td>Anti-SSA antibody, <italic>n</italic> (%)</td>
<td>18/25 (72)</td>
<td>61/103 (69.2)</td>
<td>0.238</td>
</tr>
<tr>
<td>Anti-SSB antibody, <italic>n</italic> (%)</td>
<td>3/25 (12)</td>
<td>17/103 (16.5)</td>
<td>0.803</td>
</tr>
<tr>
<td>Anti-rRNP antibody, <italic>n</italic> (%)</td>
<td>4/25 (16)</td>
<td>16/103 (15.5)</td>
<td>1.000</td>
</tr>
<tr>
<td>ACL antibody, <italic>n</italic> (%)</td>
<td>5/20 (25)</td>
<td>19/90 (21.1)</td>
<td>0.935</td>
</tr>
<tr>
<td>SLEDAI, mean± SE</td>
<td>17.27 ± 1.004</td>
<td>10.13 ± 0.63</td>
<td>0.000</td>
</tr>
<tr>
<td><italic>Traditional risk factors</italic></td>
</tr>
<tr>
<td>Diabetes, <italic>n</italic> (%)</td>
<td>1/26 (3.8)</td>
<td>8/104 (7.7)</td>
<td>0.796</td>
</tr>
<tr>
<td>Hypertension, <italic>n</italic> (%)</td>
<td>10/26 (38.5)</td>
<td>41/104 (39.4)</td>
<td>0.928</td>
</tr>
<tr>
<td>Smoking, <italic>n</italic> (%)</td>
<td>1 /26(3.8)</td>
<td>6/104 (5.8)</td>
<td>1.000</td>
</tr>
<tr>
<td>Family history of cerebrovascular diseases, <italic>n</italic> (%)</td>
<td>2/26 (7.7)</td>
<td>3 /104(2.9)</td>
<td>0.569</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313477226"><p>ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PT: prothrombin time; LA: lupus anticoagulant; ANA: anti-nuclear antibody; anti-dsDNA: anti-double-stranded DNA; ACL antibody: anti-cardiolipin antibody; SLEDAI: systemic lupus erythematosus (SLE) disease activity index.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-0961203313477226"><title>Intracranial hemorrhagic features of the case group</title>
<p>We studied the hemorrhagic features of the case group and found that the neurological manifestations of intracranial hemorrhage had a wide range and often coexisted in the same patient. Headache was the most common symptom (15/26; 57.7%), followed by disturbance of consciousness (eight of 26; 30.8%), partial paralysis (seven of 26; 26.9%), blurred vision (five of 26; 19.2%), seizures (five of 26; 19.2%), vertigo (three of 26; 11.5%), and aphasia (two of 26; 7.7%) (<xref ref-type="fig" rid="fig1-0961203313477226">Figure 1</xref>).
<fig id="fig1-0961203313477226" position="float"><label>Figure 1</label><caption><p>Neurological manifestations (by percentage) of intracranial hemorrhage in systemic lupus erythematosus (SLE) patients. Headache was the most common symptom.</p>
<p>HA: headache; DC: disturbance of consciousness; PP: partial paralysis; BV: blurred vision; SZ: seizures; VER: vertigo; AP: aphasia.</p></caption><graphic xlink:href="10.1177_0961203313477226-fig1.tif"/>
</fig></p>
<p>All 26 patients received computerized tomography (CT) or magnetic resonance imaging (MRI) inspections, and <xref ref-type="fig" rid="fig2-0961203313477226">Figure 2</xref> shows the image from one representative patient. We found that the anatomical localization of the hemorrhages in the brain varied, and many patients presented multiple hemorrhages. The cerebrum was predominantly involved. Parietal lobe, temporal lobe, occipital lobe, and frontal lobe involvement occurred in 12/26 (46.2%), eight of 26 (30.8%), six of 26 (23.1%), and three of 26 (11.5%) cases, respectively. In addition, hemorrhages occurred in the subarachnoid space (seven of 26; 26.9%), basal ganglia (three of 26; 11.5%), cerebellum (three of 26; 11.5%), external capsule (two of 26; 7.7%), and thalamus (one of 26; 3.8%) (<xref ref-type="table" rid="table2-0961203313477226">Table 2</xref>).
<fig id="fig2-0961203313477226" position="float"><label>Figure 2</label><caption><p>Computed tomography (CT) image of a 50-year-old female patient with systemic lupus erythematosus (SLE) for five months who presented with a headache. A hematoma was subsequently found in the left temporal lobe.</p></caption><graphic xlink:href="10.1177_0961203313477226-fig2.tif"/>
</fig>
<table-wrap id="table2-0961203313477226" position="float"><label>Table 2</label><caption><p>Characteristics of systemic lupus erythematosus (SLE) patients with intracranial hemorrhage</p></caption>
<graphic alternate-form-of="table2-0961203313477226" xlink:href="10.1177_0961203313477226-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>No</th>
<th>Gender</th>
<th>Age</th>
<th>Duration (month)</th>
<th>SLE manifestation</th>
<th>Neurologic manifestation<sup><xref ref-type="table-fn" rid="table-fn2-0961203313477226">a</xref></sup></th>
<th>ANA</th>
<th>Anti-ds DNA</th>
<th>Anti-ENA</th>
<th>ACL</th>
<th>LA</th>
<th>APS</th>
<th>Possible causes of hemorrhage</th>
<th>SLEDAI</th>
<th>CT/MRI<sup>b</sup></th>
<th>Treatment</th>
<th>Outcome</th>
</tr></thead>
<tbody align="left">
<tr>
<td>1</td>
<td>F</td>
<td>47</td>
<td>72</td>
<td>A, H</td>
<td>DC</td>
<td> + <sup>H</sup>1:640</td>
<td>–</td>
<td>SSA, rRNP</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>TH</td>
<td>17</td>
<td>PL, SS, CE</td>
<td>GC, MTX</td>
<td>D</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>27</td>
<td>6</td>
<td>A, S</td>
<td>DC, PP</td>
<td>+<sup>S</sup>1:160</td>
<td>–</td>
<td>SSA</td>
<td>NA</td>
<td>–</td>
<td>No</td>
<td>Secondary HBP</td>
<td>20</td>
<td>EC</td>
<td>GC, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>49</td>
<td>24</td>
<td>A, S, N</td>
<td>PP, AP</td>
<td>+<sup>S</sup> 1:1280</td>
<td>+</td>
<td>SSA, SSB, SM, RNP</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>HI</td>
<td>10</td>
<td>TL</td>
<td>GC, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>39</td>
<td>36</td>
<td>S, N</td>
<td>PP, AP, BV</td>
<td>+<sup>S</sup> 1:40</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>HI</td>
<td>18</td>
<td>TL, OL</td>
<td>GC, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>16</td>
<td>1</td>
<td>N, H</td>
<td>HA</td>
<td>+<sup>HS</sup>1:640</td>
<td>–</td>
<td>SSA</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>TH</td>
<td>11</td>
<td>TL, BG</td>
<td>GC, IVIG</td>
<td>SUR</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>42</td>
<td>84</td>
<td>O, A,S</td>
<td>DC, PP, SZ, VER</td>
<td>+<sup>HS</sup> 1:160</td>
<td>–</td>
<td>SSA, RNP</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>VA</td>
<td>23</td>
<td>PL</td>
<td>GC, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>34</td>
<td>72</td>
<td>N, H</td>
<td>HA, DC</td>
<td>+<sup>S</sup> 1:160</td>
<td>–</td>
<td>SSA, RNP</td>
<td>+</td>
<td>+</td>
<td>Yes</td>
<td>TH and DB</td>
<td>22</td>
<td>FL</td>
<td>GC, CYC, IVIG,LMWH</td>
<td>SUR</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>57</td>
<td>72</td>
<td>A, N</td>
<td>PP, VER</td>
<td>+<sup>HMS</sup>1:320</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>DB</td>
<td>20</td>
<td>PL, OL</td>
<td>GC, MMF, LMWH</td>
<td>SUR</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>14</td>
<td>7</td>
<td>A, S</td>
<td>BV, SZ</td>
<td>+<sup>S</sup> 1:1280</td>
<td>+</td>
<td>NA</td>
<td>–</td>
<td>+</td>
<td>No</td>
<td>VA</td>
<td>12</td>
<td>PL, TL,OL</td>
<td>GC, CYC, IVIG</td>
<td>SUR</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>20</td>
<td>0.4</td>
<td>A, N</td>
<td>HA, PP</td>
<td>+<sup>S</sup> 1:1280</td>
<td>+</td>
<td>SSA, SSB, SM, RNP</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>VA</td>
<td>27</td>
<td>PL, TL</td>
<td>GC, CYC, MTX</td>
<td>SUR</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>39</td>
<td>96</td>
<td>MA, P, O, A, S, N, H</td>
<td>HA</td>
<td>+<sup>S</sup> 1:1280</td>
<td>–</td>
<td>SSA, SSB, SM, RNP</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>TH</td>
<td>17</td>
<td>BG, CE</td>
<td>GC, MTX, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>31</td>
<td>156</td>
<td>MA, A, H</td>
<td>HA,BV</td>
<td>+<sup>S</sup> 1:640</td>
<td>–</td>
<td>SM, RNP</td>
<td>–</td>
<td>NA</td>
<td>No</td>
<td>TH</td>
<td>12</td>
<td>PL, OL</td>
<td>GC, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>21</td>
<td>4</td>
<td>O, S, N, H</td>
<td>DC, SZ</td>
<td>+<sup>S</sup> 1:1280</td>
<td>–</td>
<td>SM, RNP, SSA</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>TH</td>
<td>20</td>
<td>PL, OL</td>
<td>GC, IVIG</td>
<td>D</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>23</td>
<td>5</td>
<td>O, S, N, H</td>
<td>HA, BV, VER</td>
<td>+<sup>C</sup>1:1280</td>
<td>+</td>
<td>SM,RNP,SSA</td>
<td>+</td>
<td>+</td>
<td>Yes</td>
<td>TH</td>
<td>21</td>
<td>PL, TL, OL</td>
<td>GC, IVIG, CYA</td>
<td>SUR</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>55</td>
<td>84</td>
<td>S, N, H</td>
<td>SZ</td>
<td>+<sup>HS</sup> 1:320</td>
<td>–</td>
<td>SSA</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>TH</td>
<td>16</td>
<td>PL, FL</td>
<td>GC</td>
<td>D</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>29</td>
<td>144</td>
<td>MA, A</td>
<td>HA</td>
<td>+<sup>M</sup>1:640</td>
<td>+</td>
<td>SSA</td>
<td>–</td>
<td>+</td>
<td>No</td>
<td>VA</td>
<td>28</td>
<td>CE</td>
<td>GC, MMF</td>
<td>SUR</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>39</td>
<td>156</td>
<td>P, H</td>
<td>HA</td>
<td>+<sup>S</sup> 1:320</td>
<td>+</td>
<td>SSA</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>TH</td>
<td>11</td>
<td>PL</td>
<td>GC, IVIG, CYA</td>
<td>SUR</td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>50</td>
<td>36</td>
<td>S, H</td>
<td>HA</td>
<td>+<sup>S</sup> 1:160</td>
<td>–</td>
<td>SSA</td>
<td>+</td>
<td>NA</td>
<td>Yes</td>
<td>TH</td>
<td>14</td>
<td>TL</td>
<td>GC, AZA, LMWH</td>
<td>SUR</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>50</td>
<td>98</td>
<td>MA, P</td>
<td>HA, DC</td>
<td>+<sup>S</sup> 1:1280</td>
<td>+</td>
<td>RNP</td>
<td>–</td>
<td>NA</td>
<td>No</td>
<td>Primary HBP</td>
<td>10</td>
<td>BG,EC,TH</td>
<td>GC, CYC, MTX</td>
<td>D</td>
</tr>
<tr>
<td>20</td>
<td>F</td>
<td>23</td>
<td>30</td>
<td>MA, N, H</td>
<td>HA, BV</td>
<td>+<sup>S</sup> 1:1280</td>
<td>–</td>
<td>SM</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>TH</td>
<td>11</td>
<td>PL</td>
<td>GC, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>21</td>
<td>F</td>
<td>28</td>
<td>12</td>
<td>A, S, N</td>
<td>HA</td>
<td>+<sup>c</sup> 1:320</td>
<td>+</td>
<td>SSA, rRNP</td>
<td>–</td>
<td>–</td>
<td>NO</td>
<td>VA</td>
<td>24</td>
<td>SS</td>
<td>GC, MTX, LMWH</td>
<td>D</td>
</tr>
<tr>
<td>22</td>
<td>F</td>
<td>24</td>
<td>23</td>
<td>A, N</td>
<td>HA</td>
<td>+<sup>S</sup> 1:1280</td>
<td>–</td>
<td>SSA, SM, RNP, rRNP</td>
<td>–</td>
<td>–</td>
<td>NO</td>
<td>AN</td>
<td>16</td>
<td>SS, AN<sup>c</sup></td>
<td>GC, MTX, CYC, LMWH</td>
<td>SUR</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>15</td>
<td>4</td>
<td>MA, A, S, N, H</td>
<td>DC</td>
<td>+<sup>S</sup> 1:320</td>
<td>+</td>
<td>SSA, SM, RNP, rRNP</td>
<td>NA</td>
<td>+</td>
<td>Yes</td>
<td>AN and TH</td>
<td>20</td>
<td>SS, AN<sup>d</sup></td>
<td>GC, WAR</td>
<td>SUR</td>
</tr>
<tr>
<td>24</td>
<td>F</td>
<td>51</td>
<td>57</td>
<td>A, S, N</td>
<td>HA, PP</td>
<td>+<sup>S</sup>1:640</td>
<td>–</td>
<td>SSA, SM, RNP</td>
<td>–</td>
<td>–</td>
<td>No</td>
<td>AM</td>
<td>15</td>
<td>PL, FL SS</td>
<td>GC, MMF</td>
<td>SUR</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>57</td>
<td>48</td>
<td>A, N, H</td>
<td>HA</td>
<td>+<sup>H</sup>1:1280</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>NA</td>
<td>No</td>
<td>TH</td>
<td>16</td>
<td>SS</td>
<td>GC, CYC</td>
<td>SUR</td>
</tr>
<tr>
<td>26</td>
<td>F</td>
<td>55</td>
<td>240</td>
<td>N, H</td>
<td>DC, SZ</td>
<td>+<sup>HS</sup>1:1280</td>
<td>–</td>
<td>SM, RNP</td>
<td>+</td>
<td>–</td>
<td>Yes</td>
<td>TH and DB</td>
<td>18</td>
<td>SS</td>
<td>GC,CYC, MTX, LMWH</td>
<td>D</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203313477226"><label>a</label><p>Neurological manifestations caused by intracranial hemorrhage, not including those caused by other neuropsychiatric syndromes.<sup>b</sup>Computed tomography (CT) or magnetic resonance imaging (MRI) inspection showed the anatomical localization of hemorrhages. <sup>c</sup>CT angiography showed this patient had multiple aneurysms in the anterior cerebral, middle cerebral, posterior cerebral. <sup>d</sup>CT angiography showed this patient had an aneurysm in the posterior cerebral artery. F: female; M: male; MA: malar rash; P: photosensitivity; O: oral ulcers; A: arthritis; S: serositis; N: nephropathy; H: hematologic disorder; HA: headache; DC: disturbance of consciousness; PP: partial paralysis; BV: blurred vision; SZ: seizures; VER: vertigo; AP: aphasia; +<sup>H</sup>: homogeneous pattern; +<sup>S</sup>: speckled pattern; +<sup>M</sup>: membranous pattern; +<sup>C</sup>: cytoplasmic pattern; +<sup>HS</sup>: mixed pattern of homogeneous and speckled pattern; +<sup>HMS</sup>: mixed pattern of homogeneous, membranous, and speckled pattern; NA: not available; APS: antiphospholipid syndrome; TH: thrombocytopenia; HBP: hypertension; HI: hemorrhagic infarction; VA: vasculitis, DB: disturbance of blood coagulation; AN: aneurysms; AM: arteriovenous malformation; PL: parietal lobe; TL: temporal lobe; OL: occipital lobe; FL: frontal lobe; SS: subarachnoid space; BG: basal ganglia; CE: cerebellum; EC: external capsule; TH: thalamus; GC: glucocorticoid; MTX: methotrexate; CYC: cyclophosphamide; IVIG: intravenous immunoglobulin therapy; CYA: cyclosporin; MMF: mycophenolate mofetil; LMWH: low-molecular weight heparin; WAR: warfarin. SUR: survived; D: dead.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Five patients received angiography inspections. Aneurysms were detected in two patients, with one patient having multiple aneurysms in the anterior cerebral, middle cerebral, posterior cerebral, and superior cerebellar arteries, and the second patient having an aneurysm in the posterior cerebral artery (<xref ref-type="table" rid="table2-0961203313477226">Table 2</xref>).</p>
<p>We analyzed the possible causes for intracranial hemorrhage in the SLE patients carefully and found that the hemorrhagic causes were complex; some hemorrhage episodes were due to two or more causes, while others could not be well explained: 11 cases had thrombocytopenia, two had a hemorrhagic infarction, two had serious hypertension (one had arteritis secondary to SLE (CT angiography verified the stenosis and occlusion of the abdominal aorta) and one had primary hypertension), one had a disturbance of blood coagulation after anticoagulant use, two had both thrombocytopenia and a disturbance of blood coagulation after anticoagulant use, one had aneurysms, one had arteriovenous malformation (verified by surgery), and one had both an aneurysm and thrombocytopenia. In addition, five cases could not be well explained, so we inferred cerebral vasculitis might be the cause for the hemorrhage (<xref ref-type="table" rid="table2-0961203313477226">Table 2</xref>).</p>
</sec>
<sec id="sec10-0961203313477226"><title>SLE features of the case group</title>
<p>Furthermore, we found the SLE manifestations of patients with intracranial hemorrhage had unique characteristics compared to controls. SLE was more active among cases than controls. The mean ( ± SE) SLEDAI score was 17.27 ± 1.004 points (range 10–28 points) in cases and 10.13 ± 0.63 points in controls (<italic>p</italic> &lt;0.001). However, intracranial hemorrhage itself was weighted eight points in the SLEDAI score. Therefore, we excluded these eight points and found that the SLEDAI of patients in the case group ranged from two to 20 points. Therefore, these results showed that either stable or active SLE patients could suffer from intracranial hemorrhage (<xref ref-type="table" rid="table1-0961203313477226">Table 1</xref>).</p>
<p>Thrombocytopenia was present more frequently in patients in the case group than the control group (53.8 vs. 24%, <italic>p</italic> = 0.003) (<xref ref-type="table" rid="table1-0961203313477226">Table 1</xref>). Severe, moderate, and mild thrombocytopenia occurred in three (11.5%), five (19.2%), and six (23.1%) out of 26 patients of the case group, respectively, compared to five (4.8%), nine (8.7%), and 11 (10.6%) out of 104 control patients (<italic>p</italic> = 0.041).</p>
<p>The frequency of nervous system involvement (including the other neuropsychiatric manifestations defined in 1999 ACR criteria but not intracranial hemorrhage) was significantly higher among case patients than control patients (46.2 vs. 23.1%, <italic>p</italic> = 0.019). Many patients presented more than one manifestation. Specifically, there were six of 26 (23%) patients with cerebral infarction, five of 26 (19.2%) with headache, two of 26 (7.7%) with psychosis, and one of 26 (3.8%) with anxiety disorder in the case group, compared to five of 104 (4.8%) with peripheral nervous system disorders, four of 104 (3.8%) with seizures disorder, four of 104 (3.8%) with headache, three of 104 (2.9%) with psychosis, two of 104 (1.9%) with mood disorder, one of 104 (1.0%) with cerebral infarction, one of 104 (1.0%) with anxiety disorder, and one of 104 (1.0%) with cognition disorder in the control group. All symptoms in patients from the case group were carefully examined by a rheumatologist and neurologist in order to distinguish them from those caused by intracranial hemorrhage (<xref ref-type="table" rid="table1-0961203313477226">Table 1</xref>).</p>
<p>Antiphospholipid syndrome was more common in cases than controls (30.8 vs. 7.7%, <italic>p</italic> = 0.02), although the positive frequency of both aCL antibody and LA in cases and controls were similar (<italic>p</italic> &gt;0.05) (<xref ref-type="table" rid="table1-0961203313477226">Table 1</xref>).</p>
</sec>
<sec id="sec11-0961203313477226"><title>Risk factors for SLE patients with intracranial hemorrhage</title>
<p>Variables with a significant <italic>p</italic> value between two groups in the single factor analysis (including thrombocytopenia, nervous system disturbance (excluding intracranial hemorrhage), and antiphospholipid syndrome) were computed using the multivariate logistic regression model to predict the independent risk factors for SLE with intracranial hemorrhage. We found that thrombocytopenia was the independent risk factor for intracranial hemorrhage in SLE patients (odds ratio (OR) = 3.687, 95% confidence interval (CI) 1.510–9.001, <italic>p</italic> = 0.004). Therefore, the odds of getting intracranial hemorrhage in an SLE patient with thrombocytopenia were 3.687 times higher than an SLE patient without thrombocytopenia (<xref ref-type="table" rid="table3-0961203313477226">Table 3</xref>).
<table-wrap id="table3-0961203313477226" position="float"><label>Table 3</label><caption><p>Multivariable logistic regression analysis to predict risk factors for systemic lupus erythematosus (SLE) patients with intracranial hemorrhage</p></caption>
<graphic alternate-form-of="table3-0961203313477226" xlink:href="10.1177_0961203313477226-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Variable</th>
<th>OR</th>
<th>95% CL</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Thrombocytopenia</td>
<td>3.687</td>
<td>1.510, 9.001</td>
<td>0.004</td>
</tr>
<tr>
<td>Nervous system disturbance (excluding intracranial hemorrhage)</td>
<td>0.069</td>
</tr>
<tr>
<td>Antiphospholipid syndrome</td>
<td>0.074</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203313477226"><p>OR: odds ratio; 95% CL: 95% confidence limits.</p></fn>
</table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec12-0961203313477226" sec-type="discussion"><title>Discussion</title>
<p>This study investigated the largest sample size of SLE patients with intracranial hemorrhage to date. We found that the incidence of SLE with intracranial hemorrhage was very low, with only 0.39% SLE patients seen at PUMCH in recent times being diagnosed with the complication. Nevertheless, the in-hospital fatality was high, and more than one-fifth of SLE patients with intracranial hemorrhage died from the condition. Therefore, although the condition is rare, SLE with intracranial hemorrhage can be life threatening.</p>
<p>In our study, most of the patients presented with a headache, which is also the most common manifestation in all of the neuropsychiatric syndromes of SLE.<sup><xref ref-type="bibr" rid="bibr20-0961203313477226">20</xref></sup> Therefore, it is important for rheumatologists to exclude intracranial hemorrhage in SLE during their clinical work. In contrast to a general intracranial hemorrhage, the anatomical localization of the hemorrhages in the brain was predominantly located in the cerebrum, which was due to the special pathogenesis of intracranial hemorrhage in SLE. In this study, except for intracranial hemorrhage episodes caused by primary hypertension and arteriovenous malformation, all other hemorrhages were caused by reasons directly or indirectly related to SLE, including thrombocytopenia, cerebral vasculitis hemorrhagic infarction, secondary hypertension (arteritis), aneurysms, and disturbance of blood coagulation.</p>
<p>More than half of the SLE patients with intracranial hemorrhage in our study had thrombocytopenia, and we found that thrombocytopenia was an independent risk factor for SLE patients with intracranial hemorrhage. Our findings verified the inference by Bernatsky et al. that thrombocytopenia and blood coagulation disturbance may be important for cerebral hemorrhage in SLE patients.<sup><xref ref-type="bibr" rid="bibr6-0961203313477226">6</xref></sup> Several mechanisms could explain the pathogenesis of thrombocytopenia in SLE,<sup><xref ref-type="bibr" rid="bibr13-0961203313477226">13</xref>,<xref ref-type="bibr" rid="bibr21-0961203313477226">21</xref>,<xref ref-type="bibr" rid="bibr22-0961203313477226">22</xref></sup> including antibodies in platelet destruction, administration of immunosuppressive agents, antiphospholipid antibodies, thrombotic microangiopathy, bone marrow depression, and megakaryocyte maturation disorders. Moreover, these mechanisms often coexist. In addition to intracranial hemorrhage, it has been reported that thrombocytopenia in SLE patients correlates with renal disease, neuropsychiatric manifestations, and hemolytic anemia, and has a negative impact on the survival of lupus patients,<sup><xref ref-type="bibr" rid="bibr23-0961203313477226">23</xref><xref ref-type="bibr" rid="bibr24-0961203313477226"/><xref ref-type="bibr" rid="bibr25-0961203313477226"/><xref ref-type="bibr" rid="bibr26-0961203313477226"/>–<xref ref-type="bibr" rid="bibr27-0961203313477226">27</xref></sup> Therefore, thrombocytopenia in SLE patients should be closely monitored.</p>
<p>The use of anticoagulation agents is not rare in SLE patients because arterial and venous thromboembolism events are common in SLE patients, with an incidence of 6–10% in different races.<sup><xref ref-type="bibr" rid="bibr28-0961203313477226">28</xref></sup> In this study, cerebral infarction was presented in a considerable portion of SLE patients with intracranial hemorrhage. In addition, the SLE patients with intracranial hemorrhage presented higher frequency of antiphospholipid syndrome. Anticoagulation agents were used to prevent recurrent thromboembolism in these patients, which was also one of the causes for intracranial hemorrhage in SLE. Therefore, balancing the anticoagulation with bleeding risk is challenging and should be warranted, especially in cases of massive cerebral infarction or thrombocytopenia.</p>
<p>It was reported that cerebral vasculitis due to polyarteritis nodosa, Wegener’s granulomatosis, Churge-Strauss syndrome, and Bechet’s disease was a cause of intracranial hemorrhaging.<sup><xref ref-type="bibr" rid="bibr29-0961203313477226">29</xref></sup> In this study, SLE patients with intracranial hemorrhage presented other neuropsychiatric syndromes defined in 1999 ACR more frequently than controls, so cerebral vasculitis due to SLE might contribute to the occurrence of intracranial hemorrhage. In addition, in agreement with a previous case report, we also found two subarachnoid hemorrhage episodes in this study that were due to aneurysms. Although the underlying mechanism of subarachnoid hemorrhage was not well understood, the role of cerebral vasculitis should not be overlooked, because researchers have demonstrated the existence of inﬂammation in intracranial arteries in SLE patients with intracranial hemorrhage through pathological findings.<sup><xref ref-type="bibr" rid="bibr30-0961203313477226">30</xref>,<xref ref-type="bibr" rid="bibr31-0961203313477226">31</xref></sup></p>
<p>Intracranial hemorrhage in SLE patients is a rare but lethal condition. It possesses unique intracranial hemorrhage features and SLE features. As thrombocytopenia is an independent risk factor for intracranial hemorrhage coexisting with SLE, all the possible causes for thrombocytopenia in SLE patients should be controlled in order to minimize the risk of intracranial hemorrhage.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgments</title>
<p>We thank Degang Yang, MD, from XuanWu Hospital, Capital Medical University, for his assistance in analyzing neurological manifestations, and Yong Hou, Qian Wang, Dong Xu, Jing Li, Min Shen, Jinmei Su from the Department of Rheumatology, Peking Union Medical College Hospital, for their assistance in providing medical records.</p></ack>
<sec id="sec13-0961203313477226"><title>Funding</title>
<p>This study was supported by the Chinese National Key Technology R&amp;D Program, Ministry of Science and Technology (2008BAI59B02); Chinese National High Technology Research and Development Program, Ministry of Science and Technology (2012AA02A513) and the National Major Scientific and Technological Special Project for Significant New Drugs Development (2012ZX09303006-002) and Research Special Fund for Public Welfare Industry of Health (201202004).</p>
</sec>
<sec id="sec14-0961203313477226"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313477226"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Epidemiology of eight common rheumatic diseases in China: A large-scale cross-sectional survey in Beijing</article-title>. <source>Rheumatology (Oxford)</source> <year>2012</year>; <volume>51</volume>: <fpage>721</fpage>–<lpage>729</lpage>.</citation></ref>
<ref id="bibr2-0961203313477226"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>A</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>929</fpage>–<lpage>939</lpage>.</citation></ref>
<ref id="bibr3-0961203313477226"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>KY</given-names></name><name><surname>Kwok</surname><given-names>SK</given-names></name><name><surname>Ju</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>The causes of death in Korean patients with systemic lupus erythematosus over 11 years</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>989</fpage>–<lpage>997</lpage>.</citation></ref>
<ref id="bibr4-0961203313477226"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Kwok</surname><given-names>CL</given-names></name><name><surname>Ho</surname><given-names>LY</given-names></name><etal/></person-group>. <article-title>Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China</article-title>. <source>Arthritis Rheum</source> <year>2011</year>; <volume>63</volume>: <fpage>1182</fpage>–<lpage>1189</lpage>.</citation></ref>
<ref id="bibr5-0961203313477226"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>DC</given-names></name><name><surname>Santo</surname><given-names>AH</given-names></name><name><surname>Sato</surname><given-names>EI</given-names></name></person-group>. <article-title>Mortality profile related to systemic lupus erythematosus: A multiple cause-of-death analysis</article-title>. <source>J Rheumatol</source> <year>2012</year>; <volume>39</volume>: <fpage>496</fpage>–<lpage>503</lpage>.</citation></ref>
<ref id="bibr6-0961203313477226"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernatsky</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><etal/></person-group>. <article-title>Mortality related to cerebrovascular disease in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>835</fpage>–<lpage>839</lpage>.</citation></ref>
<ref id="bibr7-0961203313477226"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scalzi</surname><given-names>LV</given-names></name><name><surname>Hollenbeak</surname><given-names>CS</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2010</year>; <volume>62</volume>: <fpage>2767</fpage>–<lpage>2775</lpage>.</citation></ref>
<ref id="bibr8-0961203313477226"><label>8</label><citation citation-type="journal"><collab>The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes</collab>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>599</fpage>–<lpage>608</lpage>.</citation></ref>
<ref id="bibr9-0961203313477226"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chonan</surname><given-names>M</given-names></name><name><surname>Fujimura</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Ruptured aneurysm at the anterior wall of the internal carotid artery in a patient with systemic lupus erythematosus and secondary antiphospholipid syndrome [in Japanese]</article-title>. <source>No Shinkei Geka</source> <year>2011</year>; <volume>39</volume>: <fpage>675</fpage>–<lpage>680</lpage>.</citation></ref>
<ref id="bibr10-0961203313477226"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>SC</given-names></name><name><surname>Lee</surname><given-names>CF</given-names></name><name><surname>Lee</surname><given-names>CW</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus flare up manifestation as cerebral and spinal subarachnoid hemorrhage</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>1211</fpage>–<lpage>1213</lpage>.</citation></ref>
<ref id="bibr11-0961203313477226"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brah</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Chapon</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Subarachnoid hemorrhages form ruptured aneurysms as the presenting feature of lupus cerebral vasculitis [in French]</article-title>. <source>Rev Med Interne</source> <year>2012</year>; <volume>33</volume>: <fpage>e10</fpage>–<lpage>e13</lpage>.</citation></ref>
<ref id="bibr12-0961203313477226"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>MT</given-names></name><name><surname>Lavigne</surname><given-names>C</given-names></name><name><surname>Sorond</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Transient life-threatening cerebral edema in a patient with systemic lupus erythematosus</article-title>. <source>J Clin Rheumatol</source> <year>2009</year>; <volume>15</volume>: <fpage>181</fpage>–<lpage>184</lpage>.</citation></ref>
<ref id="bibr13-0961203313477226"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Refai</surname><given-names>D</given-names></name><name><surname>Botros</surname><given-names>JA</given-names></name><name><surname>Strom</surname><given-names>RG</given-names></name><etal/></person-group>. <article-title>Spontaneous isolated convexity subarachnoid hemorrhage: Presentation, radiological findings, differential diagnosis, and clinical course</article-title>. <source>J Neurosurg</source> <year>2008</year>; <volume>109</volume>: <fpage>1034</fpage>–<lpage>1041</lpage>.</citation></ref>
<ref id="bibr14-0961203313477226"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tardy-Poncet</surname><given-names>B</given-names></name><name><surname>Charier</surname><given-names>D</given-names></name><name><surname>Diconne</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Extremely low doses of lepirudin in a patient with heparin-induced thrombocytopenia, high bleeding risk and renal insufficiency</article-title>. <source>Br J Haematol</source> <year>2009</year>; <volume>146</volume>: <fpage>456</fpage>–<lpage>457</lpage>.</citation></ref>
<ref id="bibr15-0961203313477226"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pérard</surname><given-names>L</given-names></name><name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name><name><surname>Limal</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Hemophagocytic syndrome in a pregnant patient with systemic lupus erythematosus, complicated with preeclampsia and cerebral hemorrhage</article-title>. <source>Ann Hematol</source> <year>2007</year>; <volume>86</volume>: <fpage>541</fpage>–<lpage>544</lpage>.</citation></ref>
<ref id="bibr16-0961203313477226"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr17-0961203313477226"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Derivation of the SLEDAI: A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr18-0961203313477226"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>295</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr19-0961203313477226"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Prevalence of diabetes among men and women in China</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <fpage>1090</fpage>–<lpage>1101</lpage>.</citation></ref>
<ref id="bibr20-0961203313477226"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Unterman</surname><given-names>A</given-names></name><name><surname>Nolte</surname><given-names>JE</given-names></name><name><surname>Boaz</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neuropsychiatric syndromes in systemic lupus erythematosus: A meta-analysis</article-title>. <source>Semin Arthritis Rheum</source> <year>2011</year>; <volume>41</volume>: <fpage>1</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr21-0961203313477226"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macchi</surname><given-names>L</given-names></name><name><surname>Rispal</surname><given-names>P</given-names></name><name><surname>Clofent-Sanchez</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: Their relationship with the observed thrombocytopenia</article-title>. <source>Br J Haematol</source> <year>1997</year>; <volume>98</volume>: <fpage>336</fpage>–<lpage>341</lpage>.</citation></ref>
<ref id="bibr22-0961203313477226"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cines</surname><given-names>DB</given-names></name><name><surname>Liebman</surname><given-names>H</given-names></name><name><surname>Stasi</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Pathobiology of secondary immune thrombocytopenia</article-title>. <source>Semin Hematol</source> <year>2009</year>; <volume>46</volume>: <fpage>S2</fpage>–<lpage>S14</lpage>.</citation></ref>
<ref id="bibr23-0961203313477226"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernández</surname><given-names>M</given-names></name><name><surname>Alarcón</surname><given-names>GS</given-names></name><name><surname>Apte</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor</article-title>. <source>Arthritis Rheum</source> <year>2007</year>; <volume>56</volume>: <fpage>614</fpage>–<lpage>621</lpage>.</citation></ref>
<ref id="bibr24-0961203313477226"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reveille</surname><given-names>JD</given-names></name><name><surname>Bartolucci</surname><given-names>A</given-names></name><name><surname>Alarcón</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death</article-title>. <source>Arthritis Rheum</source> <year>1990</year>; <volume>33</volume>: <fpage>37</fpage>–<lpage>48</lpage>.</citation></ref>
<ref id="bibr25-0961203313477226"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><etal/></person-group>. <article-title>A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population</article-title>. <source>Rheumatology (Oxford)</source> <year>2000</year>; <volume>39</volume>: <fpage>399</fpage>–<lpage>406</lpage>.</citation></ref>
<ref id="bibr26-0961203313477226"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>SM</given-names></name><name><surname>Begum</surname><given-names>S</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems</article-title>. <source>Rheumatology (Oxford)</source> <year>2003</year>; <volume>42</volume>: <fpage>230</fpage>–<lpage>234</lpage>.</citation></ref>
<ref id="bibr27-0961203313477226"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jallouli</surname><given-names>M</given-names></name><name><surname>Frigui</surname><given-names>M</given-names></name><name><surname>Marzouk</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>682</fpage>–<lpage>687</lpage>.</citation></ref>
<ref id="bibr28-0961203313477226"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Tang</surname><given-names>SS</given-names></name><name><surname>To</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups</article-title>. <source>Arthritis Rheum</source> <year>2005</year>; <volume>52</volume>: <fpage>2774</fpage>–<lpage>2782</lpage>.</citation></ref>
<ref id="bibr29-0961203313477226"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Gijn</surname><given-names>J</given-names></name><name><surname>Kerr</surname><given-names>RS</given-names></name><name><surname>Rinkel</surname><given-names>GJ</given-names></name></person-group>. <article-title>Subarachnoid haemorrhage</article-title>. <source>Lancet</source> <year>2007</year>; <volume>369</volume>: <fpage>306</fpage>–<lpage>318</lpage>.</citation></ref>
<ref id="bibr30-0961203313477226"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owada</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Kita</surname><given-names>Y</given-names></name></person-group>. <article-title>Subarachnoid hemorrhage in systemic lupus erythematosus in Japan: Two case reports and a review of the literature</article-title>. <source>Mod Rheumatol</source> <year>2009</year>; <volume>19</volume>: <fpage>573</fpage>–<lpage>580</lpage>.</citation></ref>
<ref id="bibr31-0961203313477226"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giannitti</surname><given-names>C</given-names></name><name><surname>Cerase</surname><given-names>A</given-names></name><name><surname>Miracco</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Cerebral haemorrhage in a patient with systemic lupus erythematosus and vasculitis treated with intravenous immunoglobulins for a long-time and in absence of other risk factors</article-title>. <source>Clin Ter</source> <year>2011</year>; <volume>162</volume>: <fpage>125</fpage>–<lpage>127</lpage>.</citation></ref>
</ref-list>
</back>
</article>